Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POP-Study
NL-OMON58149Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of metformin, liraglutide and semaglutide in obesity and Overweight, sponsored by Erasmus MC. Primary endpoints: Change in BMI SDS over time and Change in %BMIp95 over time. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON58149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58149.